Vertex Pharmaceuticals Incorporated (VRTX): Price and Financial Metrics

Vertex Pharmaceuticals Incorporated (VRTX): $180.94

-3.13 (-1.70%)

POWR Rating

Component Grades













Add VRTX to Watchlist
Sign Up

Industry: Biotech


of 491

in industry


  • VRTX scores best on the Value dimension, with a Value rank ahead of 93.6% of US stocks.
  • VRTX's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
  • VRTX ranks lowest in Momentum; there it ranks in the 9th percentile.

VRTX Stock Summary

  • VRTX has a market capitalization of $47,752,984,484 -- more than approximately 94.15% of US stocks.
  • VRTX's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 295.13 -- higher than 90.15% of US-listed equities with positive expected earnings growth.
  • Of note is the ratio of Vertex Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; only 9.76% of US stocks have a lower such ratio.
  • Stocks that are quantitatively similar to VRTX, based on their financial statements, market capitalization, and price volatility, are REGN, NTLA, VIR, NRIX, and SGMO.
  • Visit VRTX's SEC page to see the company's official filings. To visit the company's web site, go to

VRTX Valuation Summary

  • VRTX's price/sales ratio is 7.8; this is 105.26% higher than that of the median Healthcare stock.
  • Over the past 243 months, VRTX's price/earnings ratio has gone up 70.8.
  • Over the past 243 months, VRTX's price/sales ratio has gone down 26.7.

Below are key valuation metrics over time for VRTX.

Stock Date P/S P/B P/E EV/EBIT
VRTX 2021-08-31 7.8 5.7 26.1 18.9
VRTX 2021-08-30 7.7 5.6 26.0 18.8
VRTX 2021-08-27 7.8 5.6 26.0 18.9
VRTX 2021-08-26 7.7 5.6 25.8 18.7
VRTX 2021-08-25 7.8 5.7 26.2 19.0
VRTX 2021-08-24 7.8 5.6 26.0 18.9

VRTX Growth Metrics

  • Its 4 year revenue growth rate is now at 273.05%.
  • Its 5 year price growth rate is now at 198.58%.
  • Its 3 year cash and equivalents growth rate is now at 311.88%.
VRTX's revenue has moved up $1,864,273,000 over the prior 15 months.

The table below shows VRTX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 6,683.766 2,120.568 1,991.686
2021-03-31 6,414.881 3,358.862 2,762.032
2020-12-31 6,205.683 3,253.505 2,711.647
2020-09-30 5,991.128 3,207.981 2,690.691
2020-06-30 5,402.685 2,635.022 2,080.775
2020-03-31 4,819.493 2,060.244 1,510.932

VRTX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VRTX has a Quality Grade of B, ranking ahead of 86.59% of graded US stocks.
  • VRTX's asset turnover comes in at 0.564 -- ranking 68th of 680 Pharmaceutical Products stocks.
  • ORGO, MDWD, and CCXI are the stocks whose asset turnover ratios are most correlated with VRTX.

The table below shows VRTX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.564 0.879 0.725
2021-03-31 0.565 0.881 1.066
2020-12-31 0.589 0.881 1.053
2020-09-30 0.619 0.880 1.013
2020-06-30 0.618 0.877 0.796
2020-03-31 0.607 0.872 0.605

VRTX Price Target

For more insight on analysts targets of VRTX, see our VRTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $258.59 Average Broker Recommendation 1.54 (Moderate Buy)

VRTX Stock Price Chart Interactive Chart >

Price chart for VRTX

VRTX Price/Volume Stats

Current price $180.94 52-week high $242.99
Prev. close $184.07 52-week low $176.36
Day low $180.40 Volume 1,217,100
Day high $184.96 Avg. volume 1,958,019
50-day MA $187.72 Dividend yield N/A
200-day MA $204.52 Market Cap 46.94B

Vertex Pharmaceuticals Incorporated (VRTX) Company Bio

Vertex Pharmaceuticals engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF); and advancing its research and early-stage development programs. The company was founded in 1989 and is based in Boston, Massachusetts.

VRTX Latest News Stream

Event/Time News Detail
Loading, please wait...

VRTX Latest Social Stream

Loading social stream, please wait...

View Full VRTX Social Stream

Latest VRTX News From Around the Web

Below are the latest news stories about Vertex Pharmaceuticals Inc that investors may wish to consider to help them evaluate VRTX as an investment opportunity.

CRISPR (CRSP) to Report Q3 Earnings: What's in the Cards?

On CRISPR Therapeutics' (CRSP) Q3 earnings call, investor focus will likely be on updates on the company's pipeline candidates, especially its lead candidate CTX001.

Yahoo | October 25, 2021

Vertex to Announce Third-Quarter 2021 Financial Results on November 2

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third-quarter 2021 financial results on Tuesday, November 2, 2021 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International). The conference call will be webcast live and a link to the webcast can be accessed through Vertex''s website at in the "Investors" se

Business Wire | October 22, 2021

Biotech Buyouts That Would Be Great for Investors

Any biotech acquisition is a good one -- at the right price, of course.

Yahoo | October 22, 2021

3 of the Best Stocks to Buy Now With $500

The best investing alternatives have a solid business model combined with tremendous growth prospects. You'll need nearly half of your initial $500 -- around $220 -- to buy one share of Nvidia (NASDAQ: NVDA). The obvious opportunity for Nvidia is in gaming.

Yahoo | October 22, 2021

Brokerages Anticipate Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to Announce $3.12 Earnings Per Share

Equities research analysts expect Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to post $3.12 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Eight analysts have made estimates for Vertex Pharmaceuticals earnings, with estimates ranging from $2.70 to $3.45. Vertex Pharmaceuticals reported earnings per share of $2.64 in the same quarter last year, which would []

Transcript Daily | October 21, 2021

Read More 'VRTX' Stories Here

VRTX Price Returns

1-mo -0.36%
3-mo -10.24%
6-mo -17.08%
1-year -13.15%
3-year 6.22%
5-year 133.23%
YTD -23.44%
2020 7.94%
2019 32.13%
2018 10.58%
2017 103.42%
2016 -41.45%

Continue Researching VRTX

Want to see what other sources are saying about Vertex Pharmaceuticals Inc's financials and stock price? Try the links below:

Vertex Pharmaceuticals Inc (VRTX) Stock Price | Nasdaq
Vertex Pharmaceuticals Inc (VRTX) Stock Quote, History and News - Yahoo Finance
Vertex Pharmaceuticals Inc (VRTX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9388 seconds.